5-week combined aerobic and strength exercise after bariatric surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, prospective, non-randomized controlled trial will enroll 84 adults (18–60 years) who had sleeve gastrectomy or Roux-en-Y gastric bypass and have a medical indication for metabolic rehabilitation. Participants are allocated to an intervention group that completes a supervised concurrent (aerobic + resistance) exercise program twice weekly for 5 weeks or to a control group receiving usual care without a structured exercise program. Outcomes include rectus femoris muscle quality as the primary endpoint, with secondary measures of body composition, functional response, quality of life, and adherence-related dose-response effects. Assessments occur at baseline (postoperative week 4) and 7 weeks later (after the 5-week intervention plus one week of rest).

Why it matters

Who can join: the full rules

Inclusion Criteria

* Adults aged 18-60 years.
* Participants eligible for the institutional PAD (Pago Asociado a Diagnóstico) bariatric surgery program with medical indication for metabolic rehabilitation.
* Undergoing sleeve gastrectomy or Roux-en-Y gastric bypass at Clínica BUPA Santiago.
* Medical indication for metabolic rehabilitation.
* Able and willing to provide written informed consent.

Exclusion Criteria

* Type 1 diabetes mellitus or type 2 diabetes mellitus with severe complications (including stage G4-G5 nephropathy, severe autonomic neuropathy, or high risk of exercise-related hypoglycemia).
* Severe musculoskeletal disorders limiting participation in the exercise program.
* Acute cardiovascular event within the previous 3 months or medical contraindication to supervised exercise.
* Severe cardiorespiratory disease or dyspnea at rest or with minimal exertion.
* Dependence on supplemental oxygen.
* Bariatric surgery complications (e.g., leak, bleeding, stenosis, or intra-abdominal abscess).
* Liver failure, kidney failure, or any other clinical condition compromising safe participation in the exercise program.

Where it's running

• Clínica BUPA, Santiago
  Santiago, Santiago Metropolitan, Chile Recruiting

Study contacts

• Principal investigator: María José Pabst Pérez, MSc — Universidad Autónoma de Chile
• Study coordinator: María José Pabst Perez, MSc
• Email: majose.pabst@gmail.com
• Phone: +56950023025

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.